Sellas Life Sciences signaled a catalyst-heavy 2026, reporting year-end 2025 financials while positioning two late-stage AML programs for pivotal readouts and expansion. The phase 3 REGAL study of GPS, a WT1-targeted immunotherapy in AML patients in complete remission after second-line salvage, is approaching its event-driven final analysis after recording 72 of 80 required events as of late December. In parallel, Sellas has moved its CDK9 inhibitor SLS009 into earlier lines of therapy, dosing the first patient in a new 80-patient trial in newly diagnosed AML and initiating a European collaboration to study SLS009 with azacitidine/venetoclax. The company closed 2025 with $71.8 million in cash and added $42.6 million in the first quarter of 2026 via warrant exercises, creating runway into these inflection points.
The strategy is unusually dual-pronged for a small-cap: a maintenance-style immunotherapy aiming to extend remission in a narrowly defined post-salvage setting, and a mechanism-driven backbone enhancer designed to counter venetoclax resistance biology. The question now is whether Sellas can convert scientific signals into regulatory-grade outcomes quickly enough to secure a differentiated market position in an AML landscape where standard regimens are converging and payer scrutiny of add-on therapies is intensifying.
For SLS009, early clinical evidence is doing the heavy lifting. In phase 2 data presented at ASH 2025, SLS009 combined with azacitidine/venetoclax delivered a 46% overall response rate across 35 evaluable relapsed/refractory AML patients with myelodysplasia-related changes after prior venetoclax-based treatment, including 29% complete responses or complete responses with incomplete recovery. Importantly, responses extended to difficult molecular subgroups, with observed rates of 48% in ASXL1-mutated and 57% in TP53-mutated disease. Median overall survival materially exceeded historical expectations for this population, reaching 8.9 months in the least pretreated cohort, with favorable tolerability and no dose-limiting toxicities reported. Building on these findings, Sellas is pushing SLS009 earlier, and through its January 2026 European agreement with IMPACT-AML’s STREAM network, plans to enroll approximately 40 newly diagnosed patients in a combination study beginning in the second quarter, accelerating global evidence generation.
GPS is the nearer-term binary. As an event-driven overall survival trial in a post-salvage complete remission niche, REGAL sits at the intersection of high unmet need and commercial complexity. A positive readout could establish GPS as a first- and best-in-class WT1-directed immunotherapy in AML maintenance—a space where durable benefit and manageable administration are valued by patients and clinicians, yet where treatment duration, monitoring intensity, and comparator selection will shape payer negotiations. Medical Affairs teams will need to clarify patient selection, define real-world endpoints such as MRD dynamics alongside survival, and support adherence in a maintenance context that may extend over months to years.
This push arrives amid broader hematology trends: the ascendance of azacitidine/venetoclax as a default backbone, rising resistance, renewed interest in CDK9/MCL-1 modulation, and uncertainty following setbacks to other immuno-oncology approaches in AML. On the financing side, Sellas’ heavy reliance on warrant exercises reflects a pragmatic shift toward nontraditional capital to bridge to catalysts without over-dilution, a pattern increasingly visible among late-stage biotechs awaiting binary readouts.
The near-term test is clear: if REGAL reads out positively, does Sellas convert momentum into a focused commercialization plan or strike a partnership to scale access in a specialized market; and if SLS009 continues to show activity in venetoclax-exposed and high-risk molecular segments, can the company fast-track a registrational path anchored to clear biomarker-defined populations? For competitors calibrating AML portfolios, the next quarter may determine whether a new WT1 maintenance option and a differentiated CDK9 entrant will reset the playbook—or simply raise the bar for combination strategies built on today’s backbones.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
